<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193412">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574236</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0130</org_study_id>
    <secondary_id>CO04101</secondary_id>
    <nct_id>NCT00574236</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective is to determine the effectiveness of the combination of bortezomib and
      doxorubicin in patients with metastatic breast cancer. The trial format is a single arm
      Phase II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and
      with doxorubicin IV on days 1 and 8 of a 21-day cycle.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no additional funding
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-tumor response</measure>
    <time_frame>every two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-toxicity -time to progression</measure>
    <time_frame>each cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PS-341, doxorubicin</intervention_name>
    <description>bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically or histologically confirmed metastatic breast cancer

          -  Measurable or evaluable disease

          -  Age &gt; 18, PS 0,1,2

          -  MUGA &gt; 45%

          -  Received one or fewer chemotherapies or investigational regimens for metastatic
             disease, no limit to the number of prior hormonal therapies. May have had single
             agent Herceptin and/or Herceptin plus single-agent chemotx.

          -  Must meet designated laboratory criteria within 14 days of enrollment

        Exclusion Criteria:

          -  Doxorubicin for metatstatic disease.

          -  Pregnant or lactating.

          -  Active infections, no myocardial infarction within 2 months of enrollment.

          -  Investigational drugs within 14 days of enrollment.

          -  Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within
             4 weeks of enrollment.

          -  Neuropathy that is &gt; grade 2.

          -  Active brain mets.

          -  Hypersensitivity to bortezomib, boron, or mannitol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Stewart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin PPC Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>December 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
